Pyxis Oncology, Inc. (NASDAQ:PYXS) Sees Significant Increase in Short Interest

Pyxis Oncology, Inc. (NASDAQ:PYXS) was the target of a significant growth in short interest in January. As of January 15th, there was short interest totaling 2,307,831 shares, a growth of 33.1% from the December 31st total of 1,733,403 shares. Currently, 4.1% of the company’s stock are short sold. Based on an average daily volume of 1,930,381 shares, the days-to-cover ratio is currently 1.2 days. Based on an average daily volume of 1,930,381 shares, the days-to-cover ratio is currently 1.2 days. Currently, 4.1% of the company’s stock are short sold.

Analysts Set New Price Targets

PYXS has been the topic of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a report on Thursday, January 22nd. Stephens increased their price target on shares of Pyxis Oncology from $5.00 to $8.00 and gave the stock an “overweight” rating in a research note on Monday, November 24th. HC Wainwright lifted their target price on Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Wall Street Zen lowered shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Sunday, January 25th. Finally, Stifel Nicolaus initiated coverage on Pyxis Oncology in a report on Monday, November 3rd. They issued a “buy” rating and a $9.00 target price for the company. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $7.20.

Institutional Investors Weigh In On Pyxis Oncology

Institutional investors and hedge funds have recently made changes to their positions in the company. Catalyst Funds Management Pty Ltd acquired a new position in Pyxis Oncology in the second quarter valued at approximately $26,000. Avanza Fonder AB acquired a new stake in Pyxis Oncology in the fourth quarter worth approximately $31,000. XTX Topco Ltd bought a new position in Pyxis Oncology during the second quarter valued at about $40,000. Velan Capital Investment Management LP acquired a new position in shares of Pyxis Oncology in the 2nd quarter worth approximately $44,000. Finally, Persistent Asset Partners Ltd bought a new position in shares of Pyxis Oncology in the third quarter valued at $77,000. 39.09% of the stock is owned by institutional investors and hedge funds.

Pyxis Oncology Stock Performance

Pyxis Oncology stock opened at $1.45 on Monday. The company has a market cap of $90.28 million, a price-to-earnings ratio of -0.91 and a beta of 1.45. The firm has a 50 day moving average price of $2.56 and a 200 day moving average price of $2.45. Pyxis Oncology has a 1 year low of $0.83 and a 1 year high of $5.55.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings data on Monday, November 3rd. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.01. Sell-side analysts predict that Pyxis Oncology will post -1.04 EPS for the current year.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.